(4) Subsequent events
The acquisition of Chord Therapeutics SA, Switzerland, was closed on January 31, 2022. See Note (6) “Acquisitions and divestments” for further information.
On January 19, 2022, the Group exercised an early repayment option and repaid a USD bond with a nominal value of USD 1 billion (€ 883 million) ahead of schedule. The bond was originally set to mature on March 19, 2022.
On February 7, 2022, the Group announced a change in the organizational structure of the Life Science business sector effective April 1, 2022. The existing contract development and manufacturing services and testing services, together with the respective sales and marketing, research and development, manufacturing, and supply chain functions, will be consolidated in the new Life Science Services business unit. Additionally, the existing Research Solutions and Applied Solutions business units will be combined to form the Science and Lab Solutions business unit, which will act as a third pillar alongside Process Solutions and Life Science Services.
Subsequent to the balance sheet date, no further events of special importance occurred that could have a material impact on the net assets, financial position, or results of operations.